Analyst IMS Investment Management Services Ltd. increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 43.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,380 shares of the company's stock after purchasing an additional 3,121 shares during the period. Analyst IMS Investment Management Services Ltd.'s holdings in Johnson & Johnson were worth $1,722,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently modified their holdings of JNJ. WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $29,000. Conquis Financial LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $33,000. Bernard Wealth Management Corp. purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.
Analyst Ratings Changes
Several analysts have recently weighed in on JNJ shares. Morgan Stanley increased their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Royal Bank Of Canada reissued an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $170.88.
View Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Stock Down 0.6%
Johnson & Johnson stock traded down $0.92 during mid-day trading on Friday, reaching $149.81. 22,591,152 shares of the company's stock were exchanged, compared to its average volume of 8,022,554. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a market cap of $360.44 billion, a P/E ratio of 16.66, a P/E/G ratio of 2.28 and a beta of 0.42. The company has a fifty day moving average of $154.11 and a 200-day moving average of $153.64.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.47%. Johnson & Johnson's payout ratio is 57.84%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
